Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Organon (OGN)
NYSE:OGN
OGN Stock Chart & Stats
Day’s Range― - ―
52-Week Range$13.87 - $23.10
Previous CloseN/A
Volume728.75K
Average Volume (3M)2.89M
Market Cap
$3.99B
Enterprise Value$12.96B
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)4.6
Beta0.73
Next Earnings
May 01, 2025EPS Estimate
0.93Next Dividend Ex-Date
Feb 24, 2025Dividend Yield7.32%
Share Statistics
EPS (TTM)3.33
Shares Outstanding257,538,880
10 Day Avg. Volume3,476,333
30 Day Avg. Volume2,893,582
Standard Deviation0.12
R-Squared0.09
Alpha-0.01
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)0.62
Price to Cash Flow (P/CF)7.10
P/FCF Ratio4.90
Enterprise Value/Market Cap3.25
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit3.46
Enterprise Value/Ebitda7.68
Forecast
1Y Price Target
$19.60Price Target Upside28.19% Upside
Rating ConsensusHold
Number of Analyst Covering6
---
Organon News
PremiumCompany Announcements
Organon & Co. Navigates Growth Amidst ChallengesPremiumCompany Announcements
Organon Reports 2024 Financial Results and 2025 Outlook
PremiumCompany Announcements
Organon Announces Cessation of Chief Commercial Officer Role---
Bulls Say, Bears Say
Bulls Say
Market ExpansionThe recent Dermavant transaction for VTAMA is expected to be accretive to EBITDA margin after 2025 with anticipated revenue acceleration.
Product DevelopmentNexplanon showed zero pregnancies in high BMI patients, which could raise the bar for generics, potentially exceeding $1.5bn in peak sales.
Revenue GrowthManagement noted that VTAMA AD approval could come a little early which could represent incremental product sales upside.
Bears Say
Currency ImpactSeventy-five percent of OGN revenue is ex-US, so a strengthening USD could also create a currency headwind.
Financial PerformanceBusiness development likely to be muted until 2026 as the company focuses on its balance sheet.
Market ChallengesThe key hurdle for VTAMA will be navigating a heavily (payer) managed category as the drug is not covered with 40% of plans and carries high gross-to-net deductions.
---
Ownership Overview
0.20% Insiders
21.83% Mutual Funds
17.22% Other Institutional Investors
30.12% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Legal & RegulatoryLitigation, compliance, new legislation, and taxation risks
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
OGN FAQ
What was Organon’s price range in the past 12 months?
Organon lowest stock price was $13.87 and its highest was $23.10 in the past 12 months.
What is Organon’s market cap?
Organon’s market cap is $3.99B.
When is Organon’s upcoming earnings report date?
Organon’s upcoming earnings report date is May 01, 2025 which is in 69 days.
How were Organon’s earnings last quarter?
Organon released its earnings results on Feb 13, 2025. The company reported $0.9 earnings per share for the quarter, beating the consensus estimate of $0.867 by $0.033.
Is Organon overvalued?
According to Wall Street analysts Organon’s price is currently Undervalued.
Does Organon pay dividends?
Organon pays a Quarterly dividend of $0.28 which represents an annual dividend yield of 7.32%. See more information on Organon dividends here
What is Organon’s EPS estimate?
Organon’s EPS estimate is 0.93.
How many shares outstanding does Organon have?
Organon has 257,538,880 shares outstanding.
What happened to Organon’s price movement after its last earnings report?
Organon reported an EPS of $0.9 in its last earnings report, beating expectations of $0.867. Following the earnings report the stock price went up 11.02%.
Which hedge fund is a major shareholder of Organon?
Currently, no hedge funds are holding shares in OGN
---
Organon Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$19.60 (28.19% Upside)
$19.60 (28.19% Upside)
Blogger Sentiment
Bullish
OGN Sentiment 92%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 189.2K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Negative
Last 7 Days ▲ 0.6%
Last 30 Days ▼ 1.6%
Last 30 Days ▼ 1.6%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-13.18%
12-Months-Change
Fundamentals
Return on Equity
263.89%
Trailing 12-Months
Asset Growth
15.80%
Trailing 12-Months
Company Description
Organon
Organon & Co is a science-based global pharmaceutical company that develops and delivers health solutions through a portfolio of prescription therapies within women's health, biosimilars, and established brands. Its two operating segments are the Organon Products segment and the Merck Retained Products segment. It operates in the United States, China, Japan, Korea, and countries in Europe.
---
OGN Company Deck
---
OGN Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
Organon demonstrated consistent revenue growth and strength in key segments like women's health and biosimilars. However, the company faces significant challenges, including the loss of exclusivity for Atozet, pricing pressures, and substantial one-time costs. The company is actively implementing cost-saving measures to mitigate these challenges.Read More>---
OGN Stock 12 Month Forecast
Average Price Target
$19.60
▲(28.19% Upside)
Technical Analysis
Best Analysts Covering OGN
1 Year
1 Year Success Rate
7/10 ratings generated profit
1 Year Average Return
+10.90%
reiterated a sell rating 8 days ago
Copying Jason Gerberry's trades and holding each position for 1 Year would result in 70.00% of your transactions generating a profit, with an average return of +10.90% per trade.
---